StockData
Ensysce Biosciences, Inc. logo

Ensysce Biosciences, Inc. (ENSC) stock

ENSCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.36−0.00 (-0.17%)

Close on Nov 20, 2026Market cap $7.00MP/E –Yield –

Ensysce Biosciences free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Ensysce Biosciences's free cash flow for the twelve months ending Dec 31, 2025 was -$7.93M. For fiscal 2025 it was -$7.93M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$7.93M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$1.53M–

More Ensysce Biosciences figures

See a number that looks wrong?